Pancreatic cancer is one of the deadliest forms of cancer, largely because it’s so difficult to catch early. By the time it’s ...

Mainz Biomed has the exclusive rights to develop a test for early pancreatic cancer detection using Liquid Biosciences' biomarkers.

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer Discovery Analysis Demonstrates Transformative Sensitivity of 95% ...

Mainz Biomed (MYNZ) announced it has entered into a License and Option Agreement with Liquid Biosciences to access a portfolio of novel mRNA ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic ...

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...

Welcome to the Department of Biosciences. The department delivers innovative ... Our transnational research themes are centred on: cancer biology, immunology and therapeutics; diabetes, chronic ...

Feb. 26, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced has it ...

Feb. 26, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced has it ...

Terremoto Biosciences Inc. has synthesized new 3H-imidazo[4,5-b]pyridine compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKB-α) inhibitors reported to be useful for the treatment of ...

SAN JOSE, Calif., Feb. 26, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...